Formulation Development and Evaluation of Sustained Release Tablets of Atenolol Using Natural Polymers

Abstract

Sustained release dosage forms are the most consistently exploited method of administering drugs. They reduce the frequency of dosing, severity of by-product, and release of drugs from the dosage form. The primary objective of the dosage form is to achieve a consistent blood plasma concentration level that is therapeutically active along with its non-toxic characteristics over an extended era of time. Controlled release is a dose type that provides control over the pace at which a medication is released into the systemic circulations. newlineBased on 2017 2020 data, the American Heart Association estimates 122.4 million US individuals, or 47%, would have hypertension in 2024. One in three people worldwide has hypertension, according to the WHO. The NCBI predicts a global drop in hypertension from 22.1% in 2015 to 20.3% in 2040. South-East Asia will have the greatest male frequency by 2040, while Africa will have the highest female prevalence. We expect low-income nations to have the highest occurrence in both sexes. newlineIt is effective in keeping consistent amounts of the medicine in the tissues. Sustained release medication delivery systems can reduce the dose frequency while still maintaining concentration levels in blood circulation. Benefits of sustained release include decreased irritation in the G.I.T. and improved conformity on the part of the patient. Sustained release dosage forms are more secure than other types of dosing due to their decreased variation, reduced frequency of dosing, better drug absorption, maximum utilization of drug, increased safety margin, economy, dose dumping, deficient In vitro-In vivo correlation, incorrect site of action, and inadequate In vitro-In vivo correlation. newlineOn the basis of above global datas above the on-going research depends upon the formulation and assessment of S.R. tablets of Atenolol which was introduced to replace Metoprolol that is used as an antihypertensive drug. Till date S.R. formulation of Atenolol alone is not available in market and already many formulations are